Home | All trials

[RDF data]
Trial NCT00154154

Resource URI: http://static.linkedct.org/resource/trials/NCT00154154
linkedct:arm_group <http://static.linkedct.org/resource/arm_group/16442>
linkedct:arm_group <http://static.linkedct.org/resource/arm_group/30750>
linkedct:brief_title Hope for the Chronically Suicidal Patient
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/1060>
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/7491>
linkedct:condition <http://static.linkedct.org/resource/condition/1800>
linkedct:criteria Inclusion Criteria: - Meet DSM-IV criteria for BPD - Between 18-60 years of age - Have had two parasuicide episodes in the past five years with one occurring in the past 3 months - Have had OHIP coverage for 1 year or more - Literate in English - Provide informed consent to participate in the study Exclusion Criteria: - Current active substance dependence disorder - Psychotic disorder,bipolar I disorder, or dementia - Evidence of an organic brain syndrome or mental retardation - A chronic or serious physical health problem that will require hospitalization within the next year (e.g. cancer) - A medical condition that would preclude the psychiatric medication regimen in the GPM condition - Definite plans to leave the province in the next 2 years - Currently engaged in DBT or GPM at St. Michael's Hospital
linkedct:description Suicide, a major cause of death worldwide, is a serious public health problem. Forty percent of individuals who commit suicide meet diagnostic criteria for a personality disorder and an even higher percent of those attempting suicide have a personality disorder . Borderline personality disorder (BPD) is highly associated with parasuicidal behaviour. Parasuicidal behaviour refers to suicide attempts or other self-injurious behaviour and is a risk factor for completed suicide. Approximately 69% - 80% of people diagnosed with BPD have committed at least one act of self-harm. Estimates of completed suicides in this population are about 9%, with this rate quadrupling for patients who meet 8 or more of the 9 DSM criteria for BPD. Chronically suicidal behaviour in people with BPD is estimated to be among the most expensive psychiatric disorders to treat. While there is an extensive anecdotal literature on the treatment of this population, clinical outcomes have been dismal and treatment evidence based on well-designed trials is sparse. Dialectical Behavior Therapy (DBT), a broad-based cognitive-behavioral therapy (CBT), has recently shown promise in the treatment of this population. DBT is being widely adopted in the treatment of this disorder despite its limited empirical base. To date, there are few studies on DBT and no replications of the original research on DBT by researchers independent of the treatment developer. The aim of this study is to evaluate the clinical and cost effectiveness of DBT for the treatment of parasuicidal individuals with BPD compared to a General Psychiatric Management (GPM) control condition involving a structured algorithm medication intervention plus psychosocial support. This study will compare the following outcome measures in participants who receive Dialectical Behavior Therapy versus General Psychiatric Management, Best Practices during a one-year treatment interval and two-year follow-up: (1) frequency and severity of parasuicidal behaviours ; (2) number of self-harm episodes (3) improvement in quality of life (4) cost effectiveness. Hypotheses:(1) Patients in the DBT condition will show greater reductions in the frequency and severity of parasuicidal behaviours compared to patients in the GPM condition during a one-year treatment interval and two-year follow-up; (2) Compared to GPM, DBT will result in a greater reduction in the number of self-harm episodes and a greater improvement in quality of life but will have a higher direct cost. However, because DBT will result in significant offsetting reductions in other health service costs, the incremental cost-effectiveness ratios will fall within the range of many accepted medical interventions.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers Accepts Healthy Volunteers
linkedct:eligibility_maximum_age 60 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:end_date September 2009
linkedct:enrollment 180 (xsd:int)
linkedct:firstreceived_date September 7, 2005
linkedct:has_dmc No
linkedct:id NCT00154154
linkedct:intervention <http://static.linkedct.org/resource/intervention/38286>
linkedct:intervention <http://static.linkedct.org/resource/intervention/43078>
rdfs:label Trial NCT00154154
linkedct:lastchanged_date June 20, 2008
linkedct:lead_sponsor_agency Centre for Addiction and Mental Health
linkedct:location <http://static.linkedct.org/resource/location/20304>
linkedct:location <http://static.linkedct.org/resource/location/20622>
linkedct:nct_id NCT00154154
linkedct:number_of_arms 2 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Hope for the Chronically Suicidal Patient: Evaluating the Clinical and Health Services Impact of Dialectical Behaviour Therapy in Individuals With Borderline Personality Disorder
linkedct:org_study_id CIHR: #200204MCT-101123
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/54122>
linkedct:overall_status Active, not recruiting
linkedct:oversight <http://static.linkedct.org/resource/oversight/415>
foaf:page <http://clinicaltrials.gov/show/NCT00154154>
linkedct:phase N/A
linkedct:primary_completion_date June 2007
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/65741>
linkedct:reference <http://static.linkedct.org/resource/reference/11535>
linkedct:reference <http://static.linkedct.org/resource/reference/1479>
linkedct:reference <http://static.linkedct.org/resource/reference/2195>
linkedct:reference <http://static.linkedct.org/resource/reference/2198>
linkedct:reference <http://static.linkedct.org/resource/reference/2199>
linkedct:reference <http://static.linkedct.org/resource/reference/220>
linkedct:reference <http://static.linkedct.org/resource/reference/2506>
linkedct:reference <http://static.linkedct.org/resource/reference/3022>
linkedct:reference <http://static.linkedct.org/resource/reference/3312>
linkedct:reference <http://static.linkedct.org/resource/reference/41551>
linkedct:reference <http://static.linkedct.org/resource/reference/42299>
linkedct:reference <http://static.linkedct.org/resource/reference/43664>
linkedct:secondary_id CIHR: #200204MCT-101123
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/129587>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/91014>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/91027>
linkedct:source Centre for Addiction and Mental Health
linkedct:start_date October 2002
linkedct:study_design Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
linkedct:study_type Interventional
linkedct:summary The aim of this study is to evaluate the clinical and cost effectiveness of Dialectical Behavior Therapy (DBT) for chronically suicidal behavior in individuals diagnosed with borderline personality disorder (BPD). Recent investigations of DBT have yielded positive results and have challenged the widely held opinion that the prognosis for this condition is poor. This study will consist of a two-arm randomized controlled trial that will compare DBT with a General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling. One-hundred and eighty participants will be randomly assigned to either DBT or to the GPM condition. Clinical outcomes will be assessed by changes in: (1) parasuicidal behaviour; (2) treatment retention; (3) psychiatric symptomatology; (4) anger expression; (5) social functioning and (6) health status. Cost outcomes will include an analysis of health service utilization. Clinical and cost evaluations will occur at 4-month intervals over the course of the one-year treatment and over a two-year follow-up.
rdf:type linkedct:trials
linkedct:verification_date June 2008